Genesis Research Group Appoints Tim Wright as Executive Vice President, Access and Pricing
July 1, 2025 |
Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice President, Access and Pricing. He will serve as a member of the company’s Executive Leadership Team and lead the Access & Pricing business unit.
Tim Wright brings more than 30 years of comprehensive biopharmaceutical industry experience, including 12 years in direct industry roles and 18 years in specialized pricing and market access (P&MA) consulting. His appointment reflects Genesis Research Group’s continued commitment to deepening its expertise and enhancing the value it delivers to clients navigating today’s complex market access landscape.
David Miller, Chief Executive Officer of Genesis Research Group, said: “Tim’s extensive global experience and proven track record in access and pricing strategy will be invaluable as we continue to deliver innovative solutions for our clients facing increasingly complex market challenges. We are delighted to add such an accomplished biopharmaceutical leader to our executive team and warmly welcome him to Genesis Research Group.”
Over a distinguished career, Tim Wright has successfully managed multidisciplinary teams across major markets including the United States, United Kingdom, Europe, and Asia. An economist by training, he has directed more than 1,000 client engagements spanning major therapeutic areas, including rare disease indications—a breadth of expertise that uniquely positions him to drive strategic initiatives and deliver innovative solutions for the company’s client portfolio.
Tim Wright, Executive Vice President, Access and Pricing commented: ‘I am so pleased to have joined the team at this important time in the bioscience sector. Since entering the industry 30 years ago, I’ve not seen greater pressure on clients. The squeeze on prices and reticence of evaluation bodies to update methodologies to recognise full value both present huge external challenges. There is also significant internal pressure to fill portfolio gaps, accelerate access at the sub-national level, and access revenues from less traditional markets. We are in the absolute sweet spot to partner with our clients – highly experienced methodologists, scientists and strategists combined with technology and a real desire across the whole team to excel in all we do. I am delighted to be leading the A&P team in our partnerships with clients large and small.’
Tim Wright’s appointment reflects Genesis Research Group’s commitment to strengthening its capabilities and expanding its service offerings to meet the growing demands of the biopharmaceutical sector. As the leader of the Access & Pricing business unit, Tim Wright succeeds Dr. Kuldeep Kumar Singh, who continues to work with Genesis in a part-time advisory role.
For further details of Genesis Research Group’s Access and Pricing services, please visit their website or contact solutions@genesisrg.com.
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence…
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it…
MFN Pricing Is Moving Fast – Here’s What Matters
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot to digest. In a new…
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on…
Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright’s HEOR Theater presentation ‘MFN Pricing: More Fun to Navigate – A European Roadmap to Success,’ with potentially…
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10…
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation…
Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Genesis Research Group Appoints Tim Wright as Executive Vice President, Access and Pricing
Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice…
Navigating US market access analytics: A conversation with Ki Park
In the rapidly evolving landscape of healthcare and pharmaceutical market access, data analytics has become a critical component for making informed decisions. We sat down with Ki Park, our Vice…